Effect of sodium-glucose cotransporter-2 inhibitors on blood pressure in patients with heart failure: a systematic review and meta-analysis
Abstract Background Recent studies have shown that sodium-glucose cotransporter-2 inhibitors (SGLT2i) can achieve significant improvement in blood pressure in people with diabetes. Furthermore, randomized controlled trials (RCTs) have established that SGLT2i have a cardioprotective effect in adults...
Main Authors: | Min Li, Tieci Yi, Fangfang Fan, Lin Qiu, Zhi Wang, Haoyu Weng, Wei Ma, Yan Zhang, Yong Huo |
---|---|
Format: | Article |
Language: | English |
Published: |
BMC
2022-07-01
|
Series: | Cardiovascular Diabetology |
Subjects: | |
Online Access: | https://doi.org/10.1186/s12933-022-01574-w |
Similar Items
-
Sodium–glucose cotransporters: Functional properties and pharmaceutical potential
by: Ryuhei Sano, et al.
Published: (2020-07-01) -
Sodium‐glucose cotransporter‐2 inhibitors in heart failure: an updated meta‐analysis
by: Yang Cao, et al.
Published: (2022-06-01) -
Sodium-Glucose Cotransporter 2 Inhibitors and Heart Failure: A Bedside-to-Bench Journey
by: Donato Cappetta, et al.
Published: (2021-12-01) -
Review on sodium-glucose cotransporter 2 inhibitor (SGLT2i) in diabetes mellitus and heart failure
by: Akshyaya Pradhan, et al.
Published: (2019-01-01) -
Sodium-Glucose Cotransporter-2 Inhibitors in Heart Failure with Malnutrition, Frailty, Sarcopenia, or Cachexia
by: Yu Horiuchi, et al.
Published: (2024-03-01)